Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buparlisib + capmatinib
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Buparlisib + capmatinib is a combination of two targeted therapies. Capmatinib (INC280) is an oral, small molecule inhibitor of c-MET (mesenchymal-epithelial transcription factor), while buparlisib (BKM120) is an oral, pan-class I PI3K inhibitor. This combination was investigated for the treatment of recurrent glioblastoma with homozygous phosphatase and tensin homolog (PTEN) deletion, mutation, or protein loss.
- Other names
- capmatinib + buparlisibINC280 + BKM120
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on buparlisib + capmatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buparlisib + capmatinib.